BioAtla, Inc. (BOATS:BCAB) Financings

BioAtla, Inc.

Financings

RaiseDate
Pre-paid advance convertible into common stock
Closed: US$7.13M raised · Tungsten Advisors
Dealers: Tungsten Advisors (lead)
Buyers: Yorkville Advisors Global (affiliate) (part of an aggregate $7.5 million advance); Anson Advisors Inc. (funds managed by) (part of an aggregate $7.5 million advance)
Use of proceeds: Support operations while finalizing a strategic partnership
Nov 21, 2025
Common stock under Standby Equity Purchase Agreement
Announced: Tungsten Advisors
Dealers: Tungsten Advisors (lead)
Buyers: Yorkville Advisors Global (affiliate) (commitment to buy up to a total of $15 million of common stock if the Company exercises its option)
Use of proceeds: Support operations while finalizing a strategic partnership
Nov 21, 2025
Registered direct offering of shares of common stock with accompanying warrants
Announced: about US$9.2M · US$0.952 a share · Warrants at US$1.19 for 66 months · Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC)
Dealers: Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) (lead)
Use of proceeds: Research and development including BA3182 and mecbotamab vedotin data readouts, partnering activities, working capital and general corporate purposes
Dec 20, 2024

Read by 6ix AI from the company's releases